Vadastuximab Talirine + Hypomethylating Agents Active and Well Tolerated in Untreated Older Patients With AML

December 3-6, 2016; San Diego, California
In this phase I trial, vadastuximab talirine plus HMA was active in higher-risk patient subsets, including patients with advanced secondary AML and those older than 75 years of age.
Format: Microsoft PowerPoint (.ppt)
File Size: 631 KB
Released: December 8, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Celgene Corporation
Incyte
Merck & Co., Inc.
Seattle Genetics

Related Content

Jorge Cortes, MD, and Eunice S. Wang, MD, discuss their top presentation choices at ASH 2020 in acute and chronic leukemias with the greatest potential to impact clinical practice

Jorge Cortes, MD Eunice S. Wang, MD Released: March 3, 2021

Interactive online tool providing expert treatment recommendations for newly diagnosed and relapsed/refractory follicular lymphoma from CCO

John M. Burke, MD Ian W. Flinn, MD, PhD Christopher R. Flowers, MD, MS John P. Leonard, MD Jeff P. Sharman, MD Released: March 1, 2021

Clinical Care Options (CCO) expert podcast of top leukemia presentations from Hematology 2020: magrolimab in AML, asciminib in CML (ASCEMBL), ponatinib dosing in CML (OPTIC)

Jorge Cortes, MD Eunice S. Wang, MD Released: February 26, 2021

From Clinical Care Options (CCO), Drs. Jeff Sharman and John Burke review key data from studies of lymphomas and CLL treatment presented at ASH 2020

John M. Burke, MD Jeff P. Sharman, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: February 26, 2021 Expired: February 25, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue